Please assess the completion status of the following clinical trial:

Trial Title: World-wide Randomized Antibiotic Envelope Infection Prevention Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is willing to sign and date the study patient informed consent (PIC) form~* Patient is at least 18 years of age and meets age requirements per local law~* Patient is planned to undergo at least one of the following:~  a. Patient has existing cardiac implantable electronic device (CIED) and is undergoing implantable pulse generator (IPG) (including cardiac resynchronization therapy pacemaker \[CRT-P\]), implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) replacement or upgrade with a new Medtronic generator~  i. Subjects planned to have leads added, or extracted and added for upgrades can be enrolled OR~  b. Patient will undergo a de novo Medtronic CRT-D system implant per approved indications~OR~c. Patient has existing study eligible Medtronic CIED in which the pocket was not accessed within the last 365 days, and is undergoing pocket or lead revision~* Willing to provide the contact information for the physician who provides followup for his/her CIED~* Willing and able to comply with scheduled follow-up and study related activities~Exclusion Criteria:~* Known allergy to minocycline or rifampin or their derivatives, or any other known contraindications to implantation of the TYRX envelope.~* Current therapy with chronic oral immunosuppressive agents or ≥ 20mg/day of Prednisone or equivalent.~* Hemodialysis or peritoneal dialysis.~* Prior Cardiac transplantation or existing Ventricular Assist Device (VAD).~* Require long-term vascular access for any reason.~* Prior history of a CIED infection, other prosthetic device infection, or endovascular infection, including endocarditis, in the past 12 months.~* Physical, clinical, or laboratory signs or symptoms consistent with an active infection (including but not limited to pneumonia, urinary tract, cellulitis, or bacteremia)~* Systemic lupus erythematous, because minocycline has been reported to aggravate this condition~* Female patient who is pregnant, or of childbearing potential and not on a reliable form of birth control. Women of childbearing potential are required to have a negative pregnancy test within 7 days prior to device procedure~* Participation in another study that may confound the results of this study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TYRX™ envelope (Type: ACTIVE_COMPARATOR): The Medtronic TYRX™ Absorbable Antibacterial Envelope is an absorbable sterile prosthesis designed to hold a pacemaker pulse generator or defibrillator to create a stable environment when implanted in the body. The purpose of the absorbable coating is to act as a carrier for the antimicrobial agents.
- Control (Type: NO_INTERVENTION): No TYRX™ envelope, bare CIED

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete